{"hands_on_practices": [{"introduction": "Effective management of organophosphate poisoning begins with rapid clinical assessment and a clear understanding of the underlying pathophysiology. This exercise challenges you to connect a patient's signs and symptoms directly to the overstimulated receptor systems—muscarinic, nicotinic, and CNS—and use this knowledge to construct a prioritized treatment plan. Mastering this integrated reasoning is the cornerstone of effective toxicological resuscitation [@problem_id:4968498].", "problem": "A farm worker is found collapsed in a greenhouse shortly after spraying an organophosphate insecticide. On arrival, he is diaphoretic with copious oral secretions, pinpoint pupils, generalized muscle fasciculations, and a generalized tonic–clonic seizure. His heart rate (HR) is $48$ beats per minute, respiratory rate (RR) is $28$ breaths per minute with diffuse wheezes and crackles, oxygen saturation (SpO$_2$) is $86\\%$ on room air, and blood pressure (BP) is $90/50$ millimeters of mercury. You suspect organophosphate poisoning due to inhibition of acetylcholinesterase (AChE), causing accumulation of acetylcholine (ACh) at muscarinic receptors on parasympathetic end organs, nicotinic receptors at the neuromuscular junction (NMJ) and autonomic ganglia, and within the central nervous system (CNS).\n\nUsing only these fundamental facts about receptor distribution and mechanism of toxicity, choose the option that best constructs a prioritized problem list by assigning each of the following findings—miosis, diaphoresis, fasciculations, and seizures—to muscarinic, nicotinic, or CNS pathways, and that proposes a receptor-targeted antidote strategy prioritized to address the greatest immediate threats to life. Antidotes available include atropine (a competitive muscarinic antagonist that crosses the blood–brain barrier), pralidoxime (an oxime that can dephosphorylate AChE before aging, with limited CNS penetration), and a benzodiazepine (a GABA type A ($GABA_A$) receptor positive allosteric modulator) for seizures.\n\nWhich option is most appropriate?\n\nA. Problem list: muscarinic—miosis and diaphoresis; nicotinic—fasciculations; CNS—seizures. Management priority: immediately secure airway and oxygenation while rapidly titrating atropine to drying of secretions and relief of bronchospasm and bradycardia; give a benzodiazepine promptly for seizures; administer pralidoxime early to reverse peripheral nicotinic effects and prevent progression to paralysis; perform skin decontamination in parallel. Rationale: atropine does not reverse nicotinic signs, and pralidoxime has minimal CNS effect.\n\nB. Problem list: nicotinic—miosis and diaphoresis; muscarinic—fasciculations; CNS—seizures. Management priority: give pralidoxime first to reverse all features, then atropine only if bradycardia persists; avoid benzodiazepines because they may worsen respiratory depression; decontaminate after antidotes. Rationale: oxime addresses the root cause and controls seizures.\n\nC. Problem list: muscarinic—miosis; CNS—diaphoresis and seizures; nicotinic—fasciculations. Management priority: use glycopyrrolate instead of atropine to limit tachycardia and central effects; avoid pralidoxime because nicotinic effects will resolve with antimuscarinic therapy; reserve benzodiazepines unless seizures recur. Rationale: central muscarinic blockade is undesirable; antimuscarinic therapy is sufficient.\n\nD. Problem list: muscarinic—miosis and diaphoresis; nicotinic—fasciculations; CNS—seizures. Management priority: administer pralidoxime first to prevent AChE aging, then atropine for secretions and bradycardia if needed, and give benzodiazepines only if seizures persist after oxime therapy; decontaminate after antidotes. Rationale: preserving AChE function takes precedence even in unstable patients.", "solution": "The problem statement is subjected to validation.\n\n**Step 1: Extract Givens**\n-   **Patient**: Farm worker exposed to organophosphate insecticide.\n-   **Clinical Findings**: Collapsed, diaphoretic, copious oral secretions, pinpoint pupils (miosis), generalized muscle fasciculations, generalized tonic-clonic seizure.\n-   **Vital Signs**: Heart rate (HR) is $48$ beats per minute. Respiratory rate (RR) is $28$ breaths per minute with diffuse wheezes and crackles. Oxygen saturation (SpO$_2$) is $86\\%$ on room air. Blood pressure (BP) is $90/50$ millimeters of mercury.\n-   **Pathophysiological Mechanism**: Inhibition of acetylcholinesterase (AChE), leading to accumulation of acetylcholine (ACh) at:\n    1.  Muscarinic receptors on parasympathetic end organs.\n    2.  Nicotinic receptors at the neuromuscular junction (NMJ) and autonomic ganglia.\n    3.  Central nervous system (CNS).\n-   **Task**: Assign the findings (miosis, diaphoresis, fasciculations, seizures) to the correct receptor/system and propose a prioritized, receptor-targeted antidote strategy.\n-   **Available Antidotes**:\n    1.  **Atropine**: A competitive muscarinic antagonist that crosses the blood-brain barrier.\n    2.  **Pralidoxime**: An oxime that dephosphorylates AChE before aging, with limited CNS penetration.\n    3.  **Benzodiazepine**: A GABA type A (GABA$_A$) receptor positive allosteric modulator for seizures.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding**: The problem is scientifically sound. The clinical presentation is a classic toxidrome for organophosphate poisoning. The stated mechanism—AChE inhibition leading to ACh accumulation at muscarinic, nicotinic, and CNS synapses—is the established pathophysiology. The effects of the available antidotes (atropine, pralidoxime, benzodiazepine) are accurately described.\n-   **Well-Posed**: The problem is well-posed. It requires the application of fundamental pharmacological and toxicological principles to a clinical scenario to determine a logical course of action. A single best answer can be reasoned from the provided information.\n-   **Objectivity**: The problem is stated in objective, clinical terms, free of bias or subjective claims.\n\n**Step 3: Verdict and Action**\n-   **Verdict**: The problem is valid. It is scientifically grounded, well-posed, and objective. It does not violate any of the specified invalidity criteria.\n-   **Action**: Proceed with solving the problem.\n\n**Solution Derivation**\n\nThe solution requires two steps: (1) correctly mapping the patient's signs to the overstimulated receptor systems, and (2) establishing a management plan that prioritizes the most immediate life-threats according to standard resuscitation principles (Airway, Breathing, Circulation, Disability, Exposure - ABCDE).\n\n**Part 1: Constructing the Problem List (Symptom-Receptor Mapping)**\n\nBased on the fundamental principles of autonomic and neuromuscular pharmacology provided:\n-   **Miosis (pinpoint pupils)**: The sphincter pupillae muscle is innervated by parasympathetic neurons that release ACh onto muscarinic receptors. Excess ACh causes pupillary constriction. Therefore, miosis is a **muscarinic** effect.\n-   **Diaphoresis (profuse sweating)**: Sweat glands are anatomically part of the sympathetic nervous system, but they are functionally cholinergic, activated by ACh acting on **muscarinic** receptors. Therefore, diaphoresis is a muscarinic effect.\n-   **Fasciculations (muscle twitches)**: These are caused by spontaneous depolarization of skeletal muscle fibers due to excess ACh at the neuromuscular junction (NMJ). The receptors at the NMJ are **nicotinic** ($N_m$). Therefore, fasciculations are a nicotinic effect.\n-   **Seizures**: These result from widespread, uncontrolled neuronal firing in the brain. ACh is an excitatory neurotransmitter in the brain, and its excess can lead to hyperexcitability and seizures. This is a direct **CNS** effect.\n\nThe correct problem list is:\n-   Muscarinic: miosis, diaphoresis (also bradycardia, bronchorrhea, bronchospasm)\n-   Nicotinic: fasciculations\n-   CNS: seizures\n\n**Part 2: Prioritizing Management**\n\nThe patient is critically ill. Management must follow the ABCDEs of resuscitation.\n1.  **Airway and Breathing**: The patient's airway is threatened by copious secretions. Breathing is severely compromised (RR $28$, SpO$_2$ $86\\%$, wheezes, crackles) due to bronchorrhea (excess fluid in airways) and bronchospasm (constriction of airways). Both are life-threatening **muscarinic** effects. Immediate airway management (suctioning) and oxygenation are essential. The definitive antidote for these muscarinic effects is **atropine**, a muscarinic antagonist. It must be administered rapidly and titrated to the therapeutic endpoint of drying secretions and clearing the lungs.\n2.  **Disability**: The patient is having a generalized tonic-clonic seizure. Status epilepticus is a neurological emergency that can cause permanent brain damage, rhabdomyolysis, and exacerbate respiratory compromise. The standard, first-line treatment for toxic-seizures is a **benzodiazepine**, which enhances CNS inhibition via GABA$_A$ receptors. This must be given promptly to terminate seizure activity.\n3.  **Circulation**: The patient is bradycardic (HR $48$) and hypotensive (BP $90/50$ mmHg). Bradycardia is a muscarinic effect on the heart's sinoatrial node. **Atropine** will block this effect and increase the heart rate, likely improving cardiac output and blood pressure.\n4.  **Reversing the Root Cause**: The fasciculations are a nicotinic sign and are a harbinger of progressive muscle weakness and eventual paralysis, including the muscles of respiration (diaphragm, intercostals). This is due to depolarization blockade at the NMJ. **Pralidoxime**, an oxime, reactivates AChE, primarily at peripheral nicotinic sites, reversing this process. It must be given early to be effective, before the phosphorylated enzyme \"ages\" into an irreversible state. While atropine and benzodiazepines are for immediate stabilization, pralidoxime is crucial for preventing progression to respiratory paralysis and reversing muscle weakness.\n5.  **Exposure**: Decontamination (removing clothing, washing skin) is vital to stop ongoing absorption of the organophosphate. This should be performed concurrently with resuscitation, as soon as feasible, by personnel wearing appropriate protective equipment.\n\n**Conclusion of Derivation**:\nThe correct management strategy is a multi-modal, prioritized approach:\n-   Immediate supportive care for airway and breathing.\n-   Rapid administration of atropine to reverse life-threatening muscarinic effects.\n-   Prompt administration of a benzodiazepine to terminate seizures.\n-   Early administration of pralidoxime to reverse nicotinic effects and prevent paralysis.\n-   Concurrent decontamination.\n\n**Option-by-Option Analysis**\n\n**A. Problem list: muscarinic—miosis and diaphoresis; nicotinic—fasciculations; CNS—seizures. Management priority: immediately secure airway and oxygenation while rapidly titrating atropine to drying of secretions and relief of bronchospasm and bradycardia; give a benzodiazepine promptly for seizures; administer pralidoxime early to reverse peripheral nicotinic effects and prevent progression to paralysis; perform skin decontamination in parallel. Rationale: atropine does not reverse nicotinic signs, and pralidoxime has minimal CNS effect.**\n-   The problem list is correct.\n-   The management priority is correct, aligning perfectly with the ABCDEs and the specific pharmacology of the poisoning and its antidotes. It correctly prioritizes atropine and benzodiazepines for immediate life-threats while administering pralidoxime early and performing decontamination in parallel.\n-   The rationale is factually correct.\n-   This option is **Correct**.\n\n**B. Problem list: nicotinic—miosis and diaphoresis; muscarinic—fasciculations; CNS—seizures. Management priority: give pralidoxime first to reverse all features, then atropine only if bradycardia persists; avoid benzodiazepines because they may worsen respiratory depression; decontaminate after antidotes. Rationale: oxime addresses the root cause and controls seizures.**\n-   The problem list is incorrect; it reverses the muscarinic and nicotinic signs.\n-   The management priority is dangerously flawed. Prioritizing pralidoxime over atropine would fail to rapidly address the lethal respiratory compromise. Avoiding benzodiazepines for an active seizure is a grave error.\n-   The rationale is incorrect; pralidoxime does not effectively control seizures or rapidly reverse central or muscarinic signs.\n-   This option is **Incorrect**.\n\n**C. Problem list: muscarinic—miosis; CNS—diaphoresis and seizures; nicotinic—fasciculations. Management priority: use glycopyrrolate instead of atropine to limit tachycardia and central effects; avoid pralidoxime because nicotinic effects will resolve with antimuscarinic therapy; reserve benzodiazepines unless seizures recur. Rationale: central muscarinic blockade is undesirable; antimuscarinic therapy is sufficient.**\n-   The problem list is incorrect; diaphoresis is a peripheral muscarinic effect.\n-   The management priority is flawed. Avoiding pralidoxime is a critical error, as antimuscarinic therapy has no effect on nicotinic neuromuscular blockade. Reserving benzodiazepines is also incorrect for an active seizure. While glycopyrrolate is a muscarinic antagonist, its inability to cross the blood-brain barrier makes it less ideal than atropine in severe poisonings where central muscarinic effects may contribute to coma and respiratory depression.\n-   The rationale is incorrect; antimuscarinic therapy is not sufficient.\n-   This option is **Incorrect**.\n\n**D. Problem list: muscarinic—miosis and diaphoresis; nicotinic—fasciculations; CNS—seizures. Management priority: administer pralidoxime first to prevent AChE aging, then atropine for secretions and bradycardia if needed, and give benzodiazepines only if seizures persist after oxime therapy; decontaminate after antidotes. Rationale: preserving AChE function takes precedence even in unstable patients.**\n-   The problem list is correct.\n-   The management priority is dangerously flawed. It violates the fundamental principle of resuscitating the patient before addressing the root cause. Delaying atropine and benzodiazepines in this unstable patient would likely lead to death from respiratory failure or seizure complications.\n-   The rationale is false. Stabilizing the patient's airway, breathing, and circulation (with atropine) and stopping seizures (with benzodiazepines) always takes precedence over administering a slower-acting agent like pralidoxime, even if the latter addresses the primary enzymatic lesion.\n-   This option is **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4968498"}, {"introduction": "Once a treatment strategy is established, precision in dosing is paramount, especially in vulnerable populations like children. This practice moves from theory to application, requiring you to perform weight-based dose calculations for the primary antidotes, atropine and pralidoxime. You will apply critical safety checks, such as minimum and maximum dose constraints, to ensure therapeutic efficacy without causing harm [@problem_id:4968514].", "problem": "A $15\\,\\mathrm{kg}$ child presents with acute organophosphate exposure requiring immediate antidotal therapy. Use the following well-established pediatric dosing facts and standard preparation concentrations for initial dosing:\n\n- Atropine sulfate initial dose for organophosphate poisoning: $0.02\\,\\mathrm{mg/kg}$ by intravenous (IV) bolus; enforce a minimum single dose of $0.10\\,\\mathrm{mg}$ and a maximum single dose of $2.0\\,\\mathrm{mg}$. A standard pediatric atropine syringe contains $0.10\\,\\mathrm{mg/mL}$.\n- Pralidoxime chloride initial dose: $30\\,\\mathrm{mg/kg}$ IV; enforce a maximum single dose of $2.0\\,\\mathrm{g}$. After reconstitution, a standard vial provides $50\\,\\mathrm{mg/mL}$.\n\nStarting from the definitions that weight-based dosing scales the drug amount linearly with body mass and that solution concentration relates mass to volume via $C = m/V$, determine the actual initial dose volumes to administer, in milliliters, after applying the stated minimum and maximum single-dose constraints.\n\nProvide your final answer as two numbers in the order $\\big($atropine volume in $\\mathrm{mL}$, pralidoxime volume in $\\mathrm{mL}\\big)$. Round each volume to three significant figures. Express the final volumes in milliliters $\\left(\\mathrm{mL}\\right)$.", "solution": "The problem is subjected to validation against the established criteria.\n\n### Step 1: Extract Givens\n- Child's mass, $m_{\\text{child}}$: $15\\,\\mathrm{kg}$\n- Atropine sulfate initial dose, $D_{\\text{atropine}}$: $0.02\\,\\mathrm{mg/kg}$\n- Atropine minimum single dose, $m_{\\text{atropine, min}}$: $0.10\\,\\mathrm{mg}$\n- Atropine maximum single dose, $m_{\\text{atropine, max}}$: $2.0\\,\\mathrm{mg}$\n- Atropine concentration, $C_{\\text{atropine}}$: $0.10\\,\\mathrm{mg/mL}$\n- Pralidoxime chloride initial dose, $D_{\\text{pralidoxime}}$: $30\\,\\mathrm{mg/kg}$\n- Pralidoxime maximum single dose, $m_{\\text{pralidoxime, max}}$: $2.0\\,\\mathrm{g}$\n- Pralidoxime concentration, $C_{\\text{pralidoxime}}$: $50\\,\\mathrm{mg/mL}$\n- Definition of concentration: $C = m/V$, where $m$ is mass and $V$ is volume.\n- Objective: Calculate the initial dose volumes for atropine and pralidoxime in milliliters, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is examined for validity:\n- **Scientifically Grounded**: The problem presents a standard, realistic clinical scenario in toxicology. The specified drugs, patient weight, dosing regimens, and concentrations are consistent with established pharmacological and medical practice for treating organophosphate poisoning in a pediatric patient. The principles of weight-based dosing and calculating volumes from concentrations are fundamental in pharmacology.\n- **Well-Posed**: The problem is fully specified. All necessary data (mass, dose per mass, concentration, dose constraints) are provided to calculate a unique set of volumes.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language.\n\nThe problem is free of scientific unsoundness, ambiguity, and internal contradictions. It is a formalizable and relevant problem in applied pharmacology.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A solution will be derived.\n\nThe solution proceeds by calculating the required mass of each drug based on the child's weight, applying the specified dose constraints, and then calculating the volume to administer using the provided concentrations.\n\n**1. Atropine Dose Calculation**\n\nFirst, we calculate the theoretical mass of atropine based on the child's weight and the prescribed dose. Let this be $m_{\\text{atropine, calc}}$.\n$$m_{\\text{atropine, calc}} = m_{\\text{child}} \\times D_{\\text{atropine}}$$\nSubstituting the given values:\n$$m_{\\text{atropine, calc}} = 15\\,\\mathrm{kg} \\times 0.02\\,\\mathrm{mg/kg} = 0.3\\,\\mathrm{mg}$$\nNext, we must apply the minimum and maximum single-dose constraints. The calculated dose must fall within the range $[m_{\\text{atropine, min}}, m_{\\text{atropine, max}}]$.\nThe constraints are $m_{\\text{atropine, min}} = 0.10\\,\\mathrm{mg}$ and $m_{\\text{atropine, max}} = 2.0\\,\\mathrm{mg}$.\nWe check if the calculated dose, $0.3\\,\\mathrm{mg}$, satisfies the condition:\n$$0.10\\,\\mathrm{mg} \\leq 0.3\\,\\mathrm{mg} \\leq 2.0\\,\\mathrm{mg}$$\nThe condition is satisfied. Therefore, the actual administered dose, $m_{\\text{atropine, final}}$, is $0.3\\,\\mathrm{mg}$.\n\nNow, we calculate the volume of the atropine solution, $V_{\\text{atropine}}$, to be administered. The relationship between concentration, mass, and volume is $C = m/V$, which can be rearranged to $V = m/C$.\n$$V_{\\text{atropine}} = \\frac{m_{\\text{atropine, final}}}{C_{\\text{atropine}}}$$\nSubstituting the final dose and the concentration:\n$$V_{\\text{atropine}} = \\frac{0.3\\,\\mathrm{mg}}{0.10\\,\\mathrm{mg/mL}} = 3.0\\,\\mathrm{mL}$$\nRounding to three significant figures, the volume is $3.00\\,\\mathrm{mL}$.\n\n**2. Pralidoxime Dose Calculation**\n\nSimilarly, we calculate the theoretical mass of pralidoxime, $m_{\\text{pralidoxime, calc}}$.\n$$m_{\\text{pralidoxime, calc}} = m_{\\text{child}} \\times D_{\\text{pralidoxime}}$$\nSubstituting the given values:\n$$m_{\\text{pralidoxime, calc}} = 15\\,\\mathrm{kg} \\times 30\\,\\mathrm{mg/kg} = 450\\,\\mathrm{mg}$$\nNext, we apply the maximum single-dose constraint, $m_{\\text{pralidoxime, max}} = 2.0\\,\\mathrm{g}$. A minimum dose is not specified. We must ensure consistent units for comparison. We convert grams to milligrams:\n$$m_{\\text{pralidoxime, max}} = 2.0\\,\\mathrm{g} \\times \\frac{1000\\,\\mathrm{mg}}{1\\,\\mathrm{g}} = 2000\\,\\mathrm{mg}$$\nWe check if the calculated dose, $450\\,\\mathrm{mg}$, is less than or equal to the maximum dose:\n$$450\\,\\mathrm{mg} \\leq 2000\\,\\mathrm{mg}$$\nThe condition is satisfied. Therefore, the actual administered dose, $m_{\\text{pralidoxime, final}}$, is $450\\,\\mathrm{mg}$.\n\nNow, we calculate the volume of the pralidoxime solution, $V_{\\text{pralidoxime}}$, to administer.\n$$V_{\\text{pralidoxime}} = \\frac{m_{\\text{pralidoxime, final}}}{C_{\\text{pralidoxime}}}$$\nSubstituting the final dose and the concentration:\n$$V_{\\text{pralidoxime}} = \\frac{450\\,\\mathrm{mg}}{50\\,\\mathrm{mg/mL}} = 9.0\\,\\mathrm{mL}$$\nRounding to three significant figures, the volume is $9.00\\,\\mathrm{mL}$.\n\nThe final required volumes are $3.00\\,\\mathrm{mL}$ for atropine and $9.00\\,\\mathrm{mL}$ for pralidoxime.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n3.00 & 9.00\n\\end{pmatrix}\n}\n$$", "id": "4968514"}, {"introduction": "The management of organophosphate poisoning extends beyond the initial emergency phase, requiring sustained therapy and careful patient monitoring. This advanced problem delves into the principles of pharmacokinetics, specifically how to adjust a continuous infusion of pralidoxime for a patient with renal impairment. Successfully solving this demonstrates your ability to apply clearance concepts to maintain therapeutic drug levels and prevent toxicity in complex clinical scenarios [@problem_id:4968509].", "problem": "A patient with acute organophosphate poisoning is being stabilized with atropine and requires pralidoxime to reverse nicotinic effects. Pralidoxime is administered by intravenous (IV) continuous infusion following an initial loading dose. For adults with normal renal function, a commonly used maintenance infusion rate is $8\\,\\mathrm{mg/kg/h}$ to maintain a therapeutic steady-state plasma concentration. Consider a $75\\,\\mathrm{kg}$ adult in whom you wish to maintain the same steady-state plasma concentration as would be achieved in normal renal function.\n\nAssume the following pharmacokinetic facts that are applicable to pralidoxime:\n- Total body clearance is the sum of renal clearance and nonrenal clearance.\n- Under normal renal function, renal processes account for $0.90$ of the total clearance, and nonrenal processes account for $0.10$.\n- Renal clearance is proportional to Creatinine Clearance (CrCl).\n- The reference normal CrCl for dosing tables is $100\\,\\mathrm{mL/min}$.\n\nThis patient’s measured Creatinine Clearance (CrCl) is $30\\,\\mathrm{mL/min}$. To avoid drug accumulation while preserving the same steady-state plasma concentration as in normal renal function, compute the reduced pralidoxime maintenance infusion rate in milligrams per hour. Round your answer to three significant figures. Express your final answer in milligrams per hour (mg/h).", "solution": "The problem is valid. It is scientifically grounded in established pharmacokinetic principles, well-posed with sufficient and consistent data, and objectively stated.\n\nThe primary principle governing continuous intravenous (IV) infusion at steady state is that the rate of drug administration (infusion rate, $R_0$) equals the rate of drug elimination. The rate of elimination is the product of the total body clearance ($CL_{Total}$) and the steady-state plasma concentration ($C_{ss}$).\n$$R_0 = C_{ss} \\cdot CL_{Total}$$\nThe objective is to determine a new infusion rate for the patient, $R_{0, p}$, that achieves the same steady-state concentration as would be achieved with a standard infusion rate, $R_{0, n}$, in a person with normal renal function. Let the subscript '$n$' denote the normal reference state and '$p$' denote the patient's state. The condition is:\n$$C_{ss, p} = C_{ss, n}$$\nBy rearranging the steady-state equation, $C_{ss} = \\frac{R_0}{CL_{Total}}$. Thus, the condition becomes:\n$$\\frac{R_{0, p}}{CL_{Total, p}} = \\frac{R_{0, n}}{CL_{Total, n}}$$\nFrom this, we can solve for the patient's required infusion rate, $R_{0, p}$:\n$$R_{0, p} = R_{0, n} \\cdot \\frac{CL_{Total, p}}{CL_{Total, n}}$$\nThis equation shows that the new dosage rate is the original rate scaled by the ratio of the patient's total clearance to the normal total clearance.\n\nFirst, we calculate the normal infusion rate, $R_{0, n}$. The standard rate is given as $8\\,\\mathrm{mg/kg/h}$ for a $75\\,\\mathrm{kg}$ adult.\n$$R_{0, n} = 8\\,\\frac{\\mathrm{mg}}{\\mathrm{kg} \\cdot \\mathrm{h}} \\times 75\\,\\mathrm{kg} = 600\\,\\frac{\\mathrm{mg}}{\\mathrm{h}}$$\nNext, we determine the clearance ratio, $\\frac{CL_{Total, p}}{CL_{Total, n}}$. Total clearance is the sum of renal clearance ($CL_R$) and nonrenal clearance ($CL_{NR}$):\n$$CL_{Total} = CL_R + CL_{NR}$$\nFor a person with normal renal function, we are given that renal clearance accounts for $f_R = 0.90$ of total clearance, and nonrenal clearance for $f_{NR} = 0.10$.\n$$CL_{R, n} = f_R \\cdot CL_{Total, n} = 0.90 \\cdot CL_{Total, n}$$\n$$CL_{NR, n} = f_{NR} \\cdot CL_{Total, n} = 0.10 \\cdot CL_{Total, n}$$\nFor the patient, we must calculate their specific total clearance, $CL_{Total, p}$. It is a standard pharmacokinetic assumption that nonrenal clearance is not affected by changes in renal function. Therefore:\n$$CL_{NR, p} = CL_{NR, n}$$\nThe problem states that renal clearance is proportional to Creatinine Clearance (CrCl), which is a measure of renal function. This proportionality can be expressed as a ratio:\n$$\\frac{CL_{R, p}}{CL_{R, n}} = \\frac{\\mathrm{CrCl}_p}{\\mathrm{CrCl}_n}$$\nUsing the given values, $\\mathrm{CrCl}_p = 30\\,\\mathrm{mL/min}$ and the reference normal value $\\mathrm{CrCl}_n = 100\\,\\mathrm{mL/min}$:\n$$\\frac{CL_{R, p}}{CL_{R, n}} = \\frac{30\\,\\mathrm{mL/min}}{100\\,\\mathrm{mL/min}} = 0.30$$\nThe patient's renal clearance, $CL_{R, p}$, can be expressed in terms of the normal total clearance:\n$$CL_{R, p} = CL_{R, n} \\cdot \\frac{\\mathrm{CrCl}_p}{\\mathrm{CrCl}_n} = (0.90 \\cdot CL_{Total, n}) \\cdot (0.30) = 0.27 \\cdot CL_{Total, n}$$\nNow we can assemble the patient's total clearance, $CL_{Total, p}$:\n$$CL_{Total, p} = CL_{R, p} + CL_{NR, p}$$\nSubstituting the relationships we've derived:\n$$CL_{Total, p} = (0.27 \\cdot CL_{Total, n}) + (CL_{NR, n})$$\n$$CL_{Total, p} = (0.27 \\cdot CL_{Total, n}) + (0.10 \\cdot CL_{Total, n})$$\n$$CL_{Total, p} = (0.27 + 0.10) \\cdot CL_{Total, n} = 0.37 \\cdot CL_{Total, n}$$\nThe required clearance ratio is therefore:\n$$\\frac{CL_{Total, p}}{CL_{Total, n}} = 0.37$$\nThis value represents the patient's remaining total drug clearance capacity relative to normal.\n\nFinally, we calculate the adjusted infusion rate for the patient, $R_{0, p}$:\n$$R_{0, p} = R_{0, n} \\cdot \\frac{CL_{Total, p}}{CL_{Total, n}}$$\n$$R_{0, p} = 600\\,\\frac{\\mathrm{mg}}{\\mathrm{h}} \\times 0.37$$\n$$R_{0, p} = 222\\,\\frac{\\mathrm{mg}}{\\mathrm{h}}$$\nThis result has three significant figures, as requested.", "answer": "$$\\boxed{222}$$", "id": "4968509"}]}